Further studies are required to examine the relationship between LIMK2 expression and drug resistance in a broad panel of cell lines representative of high-risk neuroblastoma as well as in tumor samples from neuroblastoma patients taken before and after chemotherapy. This evidence concerns the gene LIMK2 and neoplasm.